{"filing":{"accession_number":"0001104659-26-083356","cik":"0001566044","ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"tm2620382d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926083356/tm2620382d1_8k.htm"},"events":[{"id":17755,"run_id":15920,"accession_number":"0001104659-26-083356","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16345,"accession_number":"0001104659-26-083356","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:13:38.572735+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16345,"accession_number":"0001104659-26-083356","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:13:38.572735+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-14"}]}